Federal
Recognizing July 28, 2019, as "World Hepatitis Day".
Source: Congress.gov ·
909 words in original text
Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
IV
116TH CONGRESS
1ST SESSION
H. RES. 505
Recognizing July 28, 2019, as ‘‘World Hepatitis Day’’.
IN THE HOUSE OF REPRESENTATIVES
JULY 18, 2019
Ms. MENG (for herself and Mr. JOHNSON of Georgia) submitted the following
resolution; which was referred to the Committee on Energy and Commerce
RESOLUTION
Recognizing July 28, 2019, as ‘‘World Hepatitis Day’’.
Whereas hepatitis B and hepatitis C, and the incidence of
liver disease caused by these viruses, have become urgent
problems of global proportion;
Whereas an estimated 1,340,000 people worldwide die each
year due to hepatitis;
Whereas an estimated 257,000,000 people worldwide live
with chronic hepatitis B, and an estimated 884,000 peo-
ple worldwide die each year mostly due to a liver-related
illness caused by hepatitis B;
Whereas an estimated 71,000,000 people worldwide are
chronically infected with hepatitis C, and an estimated
399,000 people worldwide die each year due to a liver-
related illness caused by hepatitis C;
VerDate Sep 11 2014
22:29 Jul 18, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR505.IH
HR505
kjohnson on DSK79L0C42 with BILLS
2
•HRES 505 IH
Whereas in the United States, up to an estimated 5,700,000
people are infected with either hepatitis B or hepatitis C,
including up to an estimated 2,200,000 chronically in-
fected with hepatitis B and up to an estimated 3,500,000
chronically infected with hepatitis C;
Whereas the Centers for Disease Control and Prevention
(CDC) estimated that there were 20,900 new acute hepa-
titis B infections and 41,200 new acute hepatitis C infec-
tions in the United States in 2016;
Whereas the CDC has found significant increases in the
transmission of new hepatitis cases in the United States
since 2010, including a 3.5-fold increase between 2010
and 2016 in reported cases of acute hepatitis C in the
United States;
Whereas chronic viral hepatitis claims thousands of lives each
year in the United States, with an estimated 18,153
deaths due to hepatitis C in the United States in 2016;
Whereas between 2015 and 2020, United States taxpayers
will spend an estimated $136,000,000,000 on hepatitis C
drugs and approximately 45 percent of which will come
from the Government;
Whereas up to an estimated 80 percent of people with acute
hepatitis C do not have any symptoms;
Whereas African Americans, Asian Americans, Pacific Island-
ers, Latinos, Native Americans, Alaska Natives, gay and
bisexual men, and persons who inject drugs intravenously
all have higher rates of chronic viral hepatitis infections
in the United States than other groups of people;
Whereas Asian Americans and Pacific Islanders bear the
greatest burden of hepatitis B-related deaths in the
United States;
VerDate Sep 11 2014
22:29 Jul 18, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR505.IH
HR505
kjohnson on DSK79L0C42 with BILLS
3
•HRES 505 IH
Whereas hepatitis C is 10 times more infectious than human
immunodeficiency virus (HIV);
Whereas hepatitis B is 50 to 100 times more infectious than
HIV;
Whereas an estimated 33 percent of people who live in the
United States and are infected with HIV are also in-
fected with hepatitis B or C;
Whereas life expectancies for persons infected with HIV have
increased with antiretroviral treatment, and liver disease,
much of which is related to hepatitis B and hepatitis C
infections, has become the most common cause of death
among this population that is not related to acquired im-
mune deficiency syndrome;
Whereas despite the fact that chronic viral hepatitis is the
most common blood-borne infection in the United States,
over half of people living with hepatitis B and hepatitis
C are unaware of their infection;
Whereas hepatitis B is preventable through vaccination, and
both hepatitis B and hepatitis C are preventable with
proper public health interventions, including programs
that offer access to sterile injection equipment for people
who inject drugs intravenously; and
Whereas the goals of ‘‘World Hepatitis Day’’ on July 28,
2019, are to—
(1) highlight the global nature of chronic viral hepa-
titis epidemics;
(2) recognize that hepatitis can be prevented and
eliminated in part through a comprehensive public edu-
cation and awareness campaign designed to identify those
at risk for, and living with, hepatitis;
VerDate Sep 11 2014
22:29 Jul 18, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR505.IH
HR505
kjohnson on DSK79L0C42 with BILLS
4
•HRES 505 IH
(3) inform patients about new treatments that are
available for hepatitis; and
(4) help increase the length and quality of life for
people diagnosed with chronic hepatitis B and hepatitis
C infections: Now, therefore, be it
Resolved, That the House of Representatives—
1
(1) supports broad access to hepatitis B and
2
hepatitis C treatments;
3
(2) supports raising awareness of the risks and
4
consequences of undiagnosed chronic hepatitis B and
5
hepatitis C infections;
6
(3) calls for a robust governmental and public
7
health response to protect the health of the approxi-
8
mately 5,700,000 people in the United States who
9
are infected with hepatitis B or C; and
10
(4) urges the Centers for Disease Control and
11
Prevention to partner with State and local health de-
12
partments to develop strategies to increase the rate
13
of hepatitis B adult vaccination and hepatitis C
14
treatment to the levels necessary to eliminate new
15
infections in the United States.
16
Æ
VerDate Sep 11 2014
22:29 Jul 18, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR505.IH
HR505
kjohnson on DSK79L0C42 with BILLS
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.